BIOFILCHEM vs DCAL: Stock Comparison

Biofil Chemicals & Pharmaceuticals Limited vs Dishman Carbogen Amcis Limited

Live data: 22 July 2026, 3:04 PM IST • Source: NSE and company filings

Dishman Carbogen Amcis Limited is the larger company by market capitalisation. Biofil Chemicals & Pharmaceuticals Limited shows a higher ROE, lower leverage and a higher ROCE, while Dishman Carbogen Amcis Limited shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biofil Chemicals & Pharmaceuticals Limited and Dishman Carbogen Amcis Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOFILCHEM is more favourable on 6 of 11 scored metrics and DCAL on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DCAL is the larger company
₹2,916 Cr vs ₹55 Cr
EPS
DCAL has higher earnings per share
₹6.22 vs ₹1.71
Revenue Growth (TTM YoY)
DCAL has faster revenue growth
18.9% vs -9.3%
EPS Growth (TTM YoY)
BIOFILCHEM has faster EPS growth
10.8% vs -49.5%
Qtr Sales Growth
DCAL has stronger quarterly sales growth
18.8% vs -9.34%
Qtr Profit Growth
BIOFILCHEM has stronger quarterly profit growth
5% vs -59.4%
ROE
BIOFILCHEM has a higher ROE
13.8% vs 1.58%
ROCE
BIOFILCHEM has a higher ROCE
15.8% vs 3.15%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOFILCHEMDCAL
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOFILCHEMDCAL
Live Price₹33.5₹186.38
Day Change-0.53%-2%
Volume1,1041.54 L
52-Week High₹46.34₹321.95
52-Week Low₹25.6₹128.5
Distance from 52W High-27.71%-42.11%

Valuation

MetricBIOFILCHEMDCAL
Market Cap₹55 Cr₹2,916 Cr
P/E Ratio30.58x
P/B Ratio0.45x
EPS₹1.71₹6.22
Book Value₹13.21₹426.9
Dividend Yield0%0%

Growth

MetricBIOFILCHEMDCAL
Revenue Growth (TTM YoY)-9.3%18.9%
EPS Growth (TTM YoY)10.8%-49.5%
Qtr Sales Growth-9.34%18.8%
Qtr Profit Growth5%-59.4%

Profitability & Leverage

MetricBIOFILCHEMDCAL
ROE13.8%1.58%
ROCE15.8%3.15%
Net Margin9.81%2.51%
Operating Margin2.29%19.3%
Debt to Equity0.14x0.46x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOFILCHEMDCAL
Promoter Holding46.79%59.32%
FII Holding0%7.45% 0.21 pp
DII Holding0.08%1.63% 0.36 pp
Public Holding53.13%31.6% 0.15 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biofil Chemicals & Pharmaceuticals Limited and Dishman Carbogen Amcis Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.